Related Experiment Videos
Rizatriptan does not change cerebral blood flow velocity during migraine attacks
1University Centre for Adaptive Disorders and Headache (UCADH), Section of Pisa I Institute of Neurology, Department of Neurosciences, University of Pisa, Via Roma 67, 56126 Pisa, Italy. s.gori@med.unipi.it
Brain Research Bulletin
|April 7, 2005
Summary
Rizatriptan effectively treats migraine attacks by targeting trigeminal nerves and blood vessels. This study found rizatriptan does not significantly alter cerebral blood flow velocity, suggesting cerebrovascular safety.
Area of Science:
- Neurology
- Pharmacology
- Vascular Medicine
Background:
- Rizatriptan is a key treatment for migraine attacks.
- Proposed mechanisms include trigeminal nerve inhibition and intracranial vasoconstriction.
- Cerebral hemodynamic effects in humans remain uncharacterized.
Purpose of the Study:
- To assess rizatriptan's impact on cerebral blood flow velocity.
- To investigate hemodynamic changes during migraine attacks post-rizatriptan administration.
- To evaluate cerebrovascular safety of rizatriptan.
Main Methods:
- Transcranial Doppler used to measure middle cerebral artery flow velocity.
- 14 patients with migraine without aura monitored during spontaneous attacks.
- Measurements taken before and after 10mg oral rizatriptan, and during pain-free periods.
Main Results:
- All patients responded to rizatriptan.
- No significant mean flow velocity changes observed between pain-free and pre-treatment phases.
- No significant differences in flow velocity after rizatriptan compared to pre-treatment or pain-free states.
Conclusions:
- Rizatriptan's antimigraine action is not linked to significant intracranial hemodynamic alterations.
- Findings support the cerebrovascular safety profile of rizatriptan.
- Rizatriptan may offer a safe treatment option for migraine without aura.